Voyager Therapeutics (NASDAQ:VYGR) Now Covered by Citigroup

Citigroup began coverage on shares of Voyager Therapeutics (NASDAQ:VYGR) in a report released on Monday morning, Marketbeat.com reports. The firm issued a buy rating and a $12.00 target price on the stock.

A number of other research analysts have also recently issued reports on VYGR. Canaccord Genuity Group reiterated a “buy” rating and set a $14.00 price objective on shares of Voyager Therapeutics in a research note on Thursday, November 14th. Leerink Partners started coverage on Voyager Therapeutics in a research report on Wednesday, October 16th. They issued an “outperform” rating and a $15.00 price target for the company. HC Wainwright reiterated a “buy” rating and issued a $30.00 price target on shares of Voyager Therapeutics in a research note on Thursday, November 14th. StockNews.com upgraded shares of Voyager Therapeutics from a “hold” rating to a “buy” rating in a research note on Monday, November 18th. Finally, Leerink Partnrs upgraded shares of Voyager Therapeutics to a “strong-buy” rating in a research note on Wednesday, October 16th. Nine investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Voyager Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $17.00.

Voyager Therapeutics Stock Up 1.0 %

Shares of VYGR stock opened at $6.93 on Monday. The firm has a market capitalization of $378.59 million, a price-to-earnings ratio of 9.76 and a beta of 0.90. The stock has a fifty day moving average of $6.53 and a 200 day moving average of $7.28. Voyager Therapeutics has a 52 week low of $5.19 and a 52 week high of $11.72.

Voyager Therapeutics (NASDAQ:VYGR) last announced its earnings results on Tuesday, November 12th. The company reported ($0.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.29. The firm had revenue of $24.63 million for the quarter, compared to analyst estimates of $12.63 million. Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%. During the same quarter in the previous year, the firm posted ($0.59) EPS. Equities research analysts anticipate that Voyager Therapeutics will post -0.92 earnings per share for the current year.

Insider Buying and Selling at Voyager Therapeutics

In other news, insider Sandell Jacquelyn Fahey sold 5,999 shares of Voyager Therapeutics stock in a transaction on Wednesday, October 2nd. The shares were sold at an average price of $5.82, for a total transaction of $34,914.18. Following the transaction, the insider now owns 86,001 shares in the company, valued at $500,525.82. This trade represents a 6.52 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Corporate insiders own 4.53% of the company’s stock.

Institutional Investors Weigh In On Voyager Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Great Point Partners LLC purchased a new stake in Voyager Therapeutics in the second quarter worth about $12,668,000. Erste Asset Management GmbH bought a new position in shares of Voyager Therapeutics during the 3rd quarter valued at approximately $6,192,000. Vanguard Group Inc. increased its holdings in Voyager Therapeutics by 27.8% in the 1st quarter. Vanguard Group Inc. now owns 3,231,698 shares of the company’s stock worth $30,087,000 after acquiring an additional 702,030 shares in the last quarter. Armistice Capital LLC raised its stake in Voyager Therapeutics by 11.3% during the 2nd quarter. Armistice Capital LLC now owns 5,200,000 shares of the company’s stock worth $41,132,000 after acquiring an additional 528,000 shares during the period. Finally, American Century Companies Inc. lifted its holdings in Voyager Therapeutics by 32.4% during the second quarter. American Century Companies Inc. now owns 1,019,332 shares of the company’s stock valued at $8,063,000 after purchasing an additional 249,659 shares in the last quarter. 48.03% of the stock is currently owned by hedge funds and other institutional investors.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.